How we treat cytomegalovirus in hematopoietic cell transplant recipients.

Boeckh, Michael and Ljungman, Per (2009) How we treat cytomegalovirus in hematopoietic cell transplant recipients. Blood, 113 (23). pp. 5711-5719. ISSN 1528-0020

Text (Complete manuscript) BoeckhMBloodManuscript061209.pdf Restricted to Repository staff only Available under License Creative Commons Attribution Non-commercial No Derivatives. Download (170kB)

Abstract

Cytomegalovirus (CMV) continues to cause major complications after hematopoietic cell transplantation (HCT). Over the past decade, most centers have adopted preemptive antiviral treatment or prophylaxis strategies to prevent CMV disease. Both strategies are effective but also have shortcomings with presently available drugs. Here, we review aspects of CMV treatment and prevention in HCT recipients, including currently used drugs and diagnostics, ways to optimize preemptive therapy strategies with quantitative polymerase chain reaction assays, the use of prophylaxis, management of CMV disease caused by wild-type or drug-resistant strains, and future strategies.

Item Type:	Article or Abstract
Additional Information:	This article is available to subscribers only via the URL above for the first 12 months following publication.
DOI:	10.1182/blood-2008-10-143560
PubMed ID:	19299333
PMCID:	PMC2700312
Keywords or MeSH Headings:	Animals; Antiviral Agents/therapeutic use; Cytomegalovirus Infections/blood; Cytomegalovirus Infections/diagnosis; Cytomegalovirus Infections/drug therapy*; Cytomegalovirus Infections/prevention & control*; Drug Resistance, Viral/drug effects; Hematopoietic Stem Cell Transplantation*; Humans; Risk Factors;
Subjects:	Health Care > Risk and Preventive Health Services > Preventive drugs Diseases > Viral diseases Therapeutics > Transplantation > Stem Cell transplantation
Depositing User:	Library Staff
Date Deposited:	14 Jan 2010 19:09
Last Modified:	14 Feb 2012 14:42
URI:	http://authors.fhcrc.org/id/eprint/300

Repository Administrators Only

View Item